ReviewOncotarget2016
Improving the clinical impact of biomaterials in cancer immunotherapy.
Review in Oncotarget, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed.
- Innovative biomaterial solutions for enhancing the efficacy of tumor immunotherapy.Immunologic research · 2026Review
- Autofluorescence lifetime of gelatin-methacrylate hydrogels is sensitive to changes in crosslinking and post-gelation pH.Frontiers in bioengineering and biotechnology · 2026Article
- Cemiplimab as First Line Therapy in Advanced Penile Squamous Cell Carcinoma: A Real-World Experience.Journal of personalized medicine · 2023Article
- Harnessing Biomaterials to Study and Direct Antigen-Specific Immunotherapy.ACS applied bio materials · 2023Review
- Nanoparticle-Based Chimeric Antigen Receptor Therapy for Cancer Immunotherapy.Tissue engineering and regenerative medicine · 2023Review
- Phage engineering and phage-assisted CRISPR-Cas delivery to combat multidrug-resistant pathogens.Bioengineering & translational medicine · 2023Review
- Recent advances in the liposomal nanovesicles based immunotherapy in the treatment of cancer: A review.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2023Review
- Sericultural By-Products: The Potential for Alternative Therapy in Cancer Drug Design.Molecules (Basel, Switzerland) · 2023Review
- Overcoming biological barriers to improve solid tumor immunotherapy.Drug delivery and translational research · 2021Review
- Engineering Therapeutic Strategies in Cancer Immunotherapy via Exogenous Delivery of Toll-like Receptor Agonists.Pharmaceutics · 2021Review
- Dendritic cell tracking and modulation.Nature materials · 2020Article
- Biotinylated Streptavidin Surface Coating Improves the Efficacy of a PLGA Microparticle-Based Cancer Vaccine.Bioconjugate chemistry · 2020Article
- Phage display as a tool for vaccine and immunotherapy development.Bioengineering & translational medicine · 2020Review
- Impact of Excipients on Stability of Polymer Microparticles for Autoimmune Therapy.Frontiers in bioengineering and biotechnology · 2020Article
- Altering Antigen Charge to Control Self-Assembly and Processing of Immune Signals During Cancer Vaccination.Frontiers in immunology · 2020Article
- Directing toll-like receptor signaling in macrophages to enhance tumor immunotherapy.Current opinion in biotechnology · 2019Review
- Pentaerythritol-based lipid A bolsters the antitumor efficacy of a polyanhydride particle-based cancer vaccine.Nanomedicine : nanotechnology, biology, and medicine · 2019Article
- T cell immunotherapy enhanced by designer biomaterials.Biomaterials · 2019Review
- Induction of anti-cancer T cell immunity by in situ vaccination using systemically administered nanomedicines.Cancer letters · 2019Review
- Designing inorganic nanomaterials for vaccines and immunotherapies.Nano today · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immunotherapies for cancer have progressed enormously over the past few decades, and hold great promise for the future. The successes of these therapies, with some patients showing durable and complete remission, demonstrate the power of harnessing the immune system to eradicate tumors. However, the effectiveness of current immunotherapies is limited by hurdles ranging from immunosuppressive strategies employed by tumors, to inadequate specificity of existing therapies, to heterogeneity of disease. Further, the vast majority of approved immunotherapies employ systemic delivery of immunomodulators or cells that make addressing some of these challenges more difficult. Natural and synthetic biomaterials - such as biocompatible polymers, self-assembled lipid particles, and implantable biodegradable devices - offer unique potential to address these hurdles by harnessing the benefits of therapeutic targeting, tissue engineering, co-delivery, controlled release, and sensing. However, despite the enormous investment in new materials and nanotechnology, translation of these ideas to the clinic is still an uncommon outcome. Here we review the major challenges facing immunotherapies and discuss how the newest biomaterials and nanotechnologies could help overcome these challenges to create new clinical options for patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.